AI Article Synopsis
- * In a study of 111 adult MM patients, those who received lenalidomide maintenance therapy showed significantly better progression-free survival (PFS) and overall survival (OS) compared to those who received no maintenance treatment.
- * Specifically, 3-year PFS was 29.9% for the lenalidomide group versus 11.2% for the no-maintenance group, while 3-year OS was 83.3% for lenalidomide versus 58.5% for no maintenance, indicating that len
Article Abstract
Maintenance therapy after first autologous transplant (autoSCT) improves progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). However, efficacy of maintenance therapy after second autoSCT is unknown. We retrospectively evaluated outcomes of 111 adult MM patients who underwent second autoSCT between January 2000 and December 2018. Lenalidomide up to 15 mg daily or subcutaneous bortezomib 1.3 mg/m every 2 weeks was considered maintenance therapy. Outcomes were compared among three groups: no-maintenance ( = 73), lenalidomide ( = 23), and bortezomib maintenance ( = 15). At a median follow-up of 58 months from second autoSCT for survival, 3-year PFS and OS for no-maintenance, lenalidomide, and bortezomib maintenance were 11.2%, 29.9%, and 0%, respectively; and 58.5%, 83.3%, and 67.5% respectively. Lenalidomide maintenance was associated with improved PFS (HR 0.46, = 0.009) and OS (HR 0.25, = 0.009) compared to no-maintenance. Lenalidomide maintenance therapy after second autoSCT appears to prolong PFS and OS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2020.1749603 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!